In conclusion, despite the fact that Keynote-061 was in fact a negative trial, it provided valuable evidence for an improved efficacy with immunotherapy in a PD-L1 enriched subgroup of patients with advanced GC, which formed the basis for a more appropriate design of subsequent large phase III trials of immunotherapy in this disease. The gene discussed is CD274; the disease is gastric cancer.